COCHLEAR LTD(COH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

COH.AU COCHLEAR LTD

Market Closed 11-15 16:12:00 AEDT

294.94

-0.61

-0.21%

High300.80	Low293.61	Vol121.10K
Open300.80	D1 Closing295.55	Amplitude2.43%
Mkt Cap19.31B	Tradable Cap19.23B	Total Shares65.46M
T/O35.78M	T/O Rate0.19%	Tradable Shares65.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"COH.AU","market":"AU","secType":"STK","nameCN":"COCHLEAR LTD","latestPrice":294.94,"timestamp":1731647520000,"preClose":295.55,"halted":0,"volume":121095,"delay":0,"nameEN":"COCHLEAR LTD","floatShares":65197728,"shares":65456163,"eps":5.429999,"marketStatus":"Market Closed","change":-0.61,"latestTime":"11-15 16:12:00 AEDT","open":300.8,"high":300.8,"low":293.61,"amount":35776345,"amplitude":0.024328,"askPrice":295.45,"askSize":1000,"bidPrice":293.7,"bidSize":30,"shortable":3,"etf":0,"ttmEps":5.429999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1731884400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":295.55,"dividendRate":0.013901,"openAndCloseTimeList":[[1731625200000,1731646800000]],"volumeRatio":0.8869102465102662,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/COH.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2483330415","title":"Cochlear Ltd-Update - Notification of Buy-Back - Coh","url":"https://stock-news.laohu8.com/highlight/detail?id=2483330415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483330415?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:23","pubTimestamp":1731619428,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUE1JFMXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2482757221","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2482757221","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482757221?lang=en_us&edition=fundamental","pubTime":"2024-11-11 14:07","pubTimestamp":1731305220,"startTime":"0","endTime":"0","summary":"It was a rough start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Monday. After finishing last week on a high note, investors were more sober today, with the ASX 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/11/here-are-the-top-10-asx-200-shares-today-529/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SIQ.AU","WRD","GMD.AU","BK7099","LNW.AU","BK7062","BK7162","COH.AU","BK7093","CMM.AU","BK7007","HMC.AU","BK7510","BK7057","BK7044","BK7104","BK7155","XJO.AU","BK7503","BK7078","BK7043","ZIP.AU","BK7005","GMG.AU","JHX.AU","MP1.AU"],"gpt_icon":0},{"id":"2481919814","title":"U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2481919814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481919814?lang=en_us&edition=fundamental","pubTime":"2024-11-07 11:53","pubTimestamp":1730951580,"startTime":"0","endTime":"0","summary":"Copyright (c) 2024 Dow Jones & Company, Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","COH.AU","BK7067","BK7126","RMD.AU","BK7511","BK4585","BK4504","RMD","BK4548","TLX.AU","ANN.AU","LU2008162690.USD","CSL.AU","BK7007","LU2177674079.SGD","BK4588","BK7508","BK4082","BK4567"],"gpt_icon":1},{"id":"2481961169","title":"Will Weakness in Cochlear Limited's (ASX:COH) Stock Prove Temporary Given Strong Fundamentals?","url":"https://stock-news.laohu8.com/highlight/detail?id=2481961169","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481961169?lang=en_us&edition=fundamental","pubTime":"2024-11-07 06:49","pubTimestamp":1730933363,"startTime":"0","endTime":"0","summary":"With its stock down 12% over the past three months, it is easy to disregard Cochlear . But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. In this article, we decided to focus on Cochlear's  ROE.ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weakness-cochlear-limiteds-asx-coh-224923291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2480883758","title":"Envoy Medical Receives FDA Approval to Start Clinical Trial for Hearing Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2480883758","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480883758?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:46","pubTimestamp":1730465188,"startTime":"0","endTime":"0","summary":"Envoy Medical  said Friday the US Food and Drug Administration approved its investigational device exemption application to start a pivotal clinical trial of the Acclaim Cochlear Implant hearing device.The Acclaim technology has an implanted sensor designed for the natural anatomy of the ear to capture sound, the company said.The Acclaim Cochlear Implant received the FDA's breakthrough device designation in 2019, the hearing health company said.Envoy shares were nearly 12% higher in recent premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COCH","COH.AU","BK4082","BK7007"],"gpt_icon":0},{"id":"2480043073","title":"Cochlear Not Yet a Pick Despite Shaking Bear -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2480043073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480043073?lang=en_us&edition=fundamental","pubTime":"2024-11-01 11:17","pubTimestamp":1730431020,"startTime":"0","endTime":"0","summary":"0317 GMT - Cochlear shakes off its bear at Macquarie but remains less attractive to the investment bank's analysts than other Australia-listed medical-technology stocks. Shares in the hearing-implant manufacturer have fallen by about 16% since August. This leaves the stock at a level implying market-share gains and profit margins in line with Macquarie analysts' expectations. However, they point out that it is trading at about 42 times EPS on a 12-month forward basis, compared with about 27 for vaccine maker CSL and 25 for breath-tech provider ResMed. Both those companies are forecast to grow fiscal 2025 EPS at a faster rate, they add. Macquarie raises its target price by 2.1% to A$289.00 and upgrades its recommendation to neutral from underperform. Shares are up 0.35% at A$284.24. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2479779063","title":"Macquarie Upgrades Cochlear to Neutral from Underperform, Price Target is AU$289","url":"https://stock-news.laohu8.com/highlight/detail?id=2479779063","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479779063?lang=en_us&edition=fundamental","pubTime":"2024-10-31 16:52","pubTimestamp":1730364741,"startTime":"0","endTime":"0","summary":"Macquarie Upgrades Cochlear to Neutral from Underperform, Price Target is AU$289","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COH.AU","MQG.AU"],"gpt_icon":0},{"id":"2479753368","title":"Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2479753368","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479753368?lang=en_us&edition=fundamental","pubTime":"2024-10-31 02:00","pubTimestamp":1730311200,"startTime":"0","endTime":"0","summary":"Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within inches of gaining Food and Drug Administration approvals and is turning its mind to an IPO.Traditional epilepsy equipment which Epiminder seeks to disrupt.  Loading...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.afr.com/street-talk/cochlear-backed-medtech-epiminder-seeks-200m-val-in-pre-ipo-raise-20241030-p5kmh3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2478614732","title":"Cochlear Affirms Up to 11% Underlying Net Profit Growth Guidance for Fiscal 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2478614732","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478614732?lang=en_us&edition=fundamental","pubTime":"2024-10-25 08:48","pubTimestamp":1729817312,"startTime":"0","endTime":"0","summary":"Cochlear  reiterated its guidance of between 6% and 11% growth in underlying net profit for fiscal 2025, according to a Friday filing with the Australian bourse.In August, Cochlear reported sales revenue growth of 12% in constant currency and underlying net profit growth of 27% for full fiscal 2024.The hearing implant manufacturer's shares were up nearly 2% in recent Friday trade.Price : $286.02, Change: $+5.20, Percent Change: +1.85%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COH.AU","AUD","BK4125","BK7007"],"gpt_icon":0},{"id":"2477832591","title":"With 51% institutional ownership, Cochlear Limited (ASX:COH) is a favorite amongst the big guns","url":"https://stock-news.laohu8.com/highlight/detail?id=2477832591","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477832591?lang=en_us&edition=fundamental","pubTime":"2024-10-24 06:24","pubTimestamp":1729722260,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Cochlear implies that they have significant influence over the company's share price. A total of 25 investors have a majority stake in the company with 45% ownership. If you want to know who really controls Cochlear Limited , then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 51% ownership. In other words, the group stands to gain the most  from their investment into the company.Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.ASX:COH Earnings and Revenue Growth October 23rd 2024. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommenda","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/51-institutional-ownership-cochlear-limited-222420248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","COH.AU"],"gpt_icon":1},{"id":"2476442952","title":"We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2476442952","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476442952?lang=en_us&edition=fundamental","pubTime":"2024-10-18 12:03","pubTimestamp":1729224239,"startTime":"0","endTime":"0","summary":"Key Insights Cochlear's Annual General Meeting to take place on 25th of October Total pay for CEO Dig Howitt includes...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/we-think-shareholders-may-consider-being-more-generous-with-21","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["COH.AU","BK7007"],"gpt_icon":0},{"id":"2475480087","title":"True North shares jump on positive activity report as Cloncurry aims for Q1 production deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2475480087","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475480087?lang=en_us&edition=fundamental","pubTime":"2024-10-14 09:58","pubTimestamp":1728871080,"startTime":"0","endTime":"0","summary":"True North Copper Ltd  has seen its share price rise more than 14% on news that mining and processing activities at the Cloncurry Copper Project  in Queensland are ramping up, as the company pushes towards production in the first quarter of 2025, once sulphide processing gets underway in the new year.True North highlighted three activities in particular: beginning with the mining of around 223,000 bank cubic metres  of overburden – achieved since mining activities kicked off from the Wallace North deposit in July.This has resulted in 22,000 tonnes of oxide ore being mined and placed on the RoM.And finally, there is the ongoing irrigation of the leach pad, with this expected to boost copper production from True North’s solvent extraction  plant.These activities show that True North is on-schedule with its production preparation, boosting the parameters of its mining restart study  produced in February, which anticipated that CCP would generate free cash flow of approximatley $200 millio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/true-north-shares-jump-on-positive-activity-report-as-cloncurry-aims-for-q1-production-deadline-2024-10-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["GAM","BK7093","CCP.AU","BCM","BCM.AU","COH.AU","TNC.AU","BK7104","BK7095","BK7007"],"gpt_icon":0},{"id":"2474725706","title":"Cochlear Limited (ASX:COH) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2474725706","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474725706?lang=en_us&edition=fundamental","pubTime":"2024-10-11 04:50","pubTimestamp":1728593418,"startTime":"0","endTime":"0","summary":"It is hard to get excited after looking at Cochlear's (ASX:COH) recent performance, when its stock has declined 11...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-coh/cochlear-shares/news/cochlear-limited-asxcoh-stock-has-shown-weakness-lately-but","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2474853797","title":"Cochlear (ASX:COH) Will Want To Turn Around Its Return Trends","url":"https://stock-news.laohu8.com/highlight/detail?id=2474853797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474853797?lang=en_us&edition=fundamental","pubTime":"2024-10-10 05:53","pubTimestamp":1728510818,"startTime":"0","endTime":"0","summary":"Did you know there are some financial metrics that can provide clues of a potential multi-bagger?Amongst other things, we'll want to see two things; firstly, a growing return on capital employed  and secondly, an expansion in the company's amount of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. So when we looked at Cochlear , they do have a high ROCE, but we weren't exactly elated from how returns are trending.If you haven't worked with ROCE before, it measures the 'return'  a company generates from capital employed in its business. To calculate this metric for Cochlear, this is the formula:. Return on Capital Employed = Earnings Before Interest and Tax  ÷ . So, Cochlear has an ROCE of 24%.  In absolute terms that's a great return and it's even better than the Medical Equipment industry average of 6.9%.Above you can see how the current ROCE for Cochlear compares to its prior","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cochlear-asx-coh-want-turn-215338082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["EBIT","COH.AU","BK7007"],"gpt_icon":1},{"id":"2473416020","title":"Have these dogs of the ASX fallen too far?","url":"https://stock-news.laohu8.com/highlight/detail?id=2473416020","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473416020?lang=en_us&edition=fundamental","pubTime":"2024-10-08 00:00","pubTimestamp":1728316800,"startTime":"0","endTime":"0","summary":"One advantage that individual investors have over professionals is that they don’t need to think in quarters. We don’t even need to think in single years – or in any arbitrary period of time for that ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.morningstar.com.au/insights/stocks/255794/have-these-dogs-of-the-asx-fallen-too-far","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BPT.AU","BK7089","BK7142","BK7507","BK4213","COH.AU","BPT","NHF.AU","BK7007"],"gpt_icon":0},{"id":"2472609487","title":"BUZZ-Australia's Cochlear up after Citi upgrades stock on sustained pace of growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2472609487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472609487?lang=en_us&edition=fundamental","pubTime":"2024-10-04 11:21","pubTimestamp":1728012060,"startTime":"0","endTime":"0","summary":"** Shares of hearing implants maker Cochlear    rise as much as 1.5% to A$291.92    ** Citi upgrades stock to \"neutral\" from \"sell\", raises PT to A$305/shr from A$255/shr   ** \"We expect COH to be able to maintain pace of revenue and profit growth, driven by double-digit growth in the Adults/Seniors market and single-digit growth in Children segment,\" Citi analysts write    ** We assume that COH can maintain 10% growth for longer - Citi     ** Co reported 27% jump in FY24 profit, but FY25 profit forecast missed market expectations; stock tanked over ~13% since mid-August        ** Analysts rate stock \"hold\" on avg; median PT A$283.00 – LSEG data   ** COH has fallen ~2.4% YTD  ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAO.AU","XKO.AU","XJO.AU","COH.AU"],"gpt_icon":0},{"id":"2472675209","title":"Cochlear Shakes Bear on Revenue Growth Prospects -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2472675209","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472675209?lang=en_us&edition=fundamental","pubTime":"2024-10-04 07:36","pubTimestamp":1727998560,"startTime":"0","endTime":"0","summary":"2336 GMT - Cochlear shakes off its bear at Citi on the assumption that the hearing-implant manufacturer can maintain the pace of revenue growth set over the past decade. Noting a 13% share-price decline since the Australia-listed company's annual result announcement, analyst Mathieu Chevrier tells clients that he thinks Cochlear can keep growing annual revenue at the 10% seen over the past decade. He writes in a note that ongoing investment in sales and marketing, coupled with R&D, should support this growth. Citi lifts its target price 20% to A$305.00 and raises its recommendation to neutral from sell. Shares are at A$287.70 ahead of the open. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COH.AU"],"gpt_icon":0},{"id":"2470880432","title":"Cochlear (ASX:COH) Announces New CFO and Share Buyback Program, Signaling Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2470880432","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470880432?lang=en_us&edition=fundamental","pubTime":"2024-09-25 13:55","pubTimestamp":1727243746,"startTime":"0","endTime":"0","summary":"The Cochlear  is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a 27% increase in profit and significant R&D investments, juxtaposed against slowing emerging market growth and inventory write-downs. In the discussion that follows, we will explore Cochlear's financial health, operational inefficiencies, strategic growth initiatives, and external threats to provide a comprehensive overview of the company's current business situation.Dive into the specifics of Cochlear here with our thorough analysis report.Weaknesses: Critical Issues Affecting Cochlear's Performance and Areas For Growth. Cochlear has several avenues for growth. Market expansion efforts, particularly in countries where the Osia system is not yet available, present si","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cochlear-asx-coh-announces-cfo-055546035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","COH.AU"],"gpt_icon":0},{"id":"2469185282","title":"Australian Healthcare Players See Wage Indexation Benefits, Margin Expansion in Fiscal 2025, Jarden Research Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2469185282","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469185282?lang=en_us&edition=fundamental","pubTime":"2024-09-23 06:04","pubTimestamp":1727042683,"startTime":"0","endTime":"0","summary":"Australian healthcare players Integral Diagnostics  and Capitol Health  should benefit from additional wage indexation in fiscal 2025, while Sonic Healthcare  and Healius  are expected to remain \"hurt\" by the lack of indexation, according to a Sept. 18 note from Jarden Research.Meanwhile, Ramsay Healthcare  and Regis Healthcare  should benefit from lower agency costs, with Ramsay remaining in negotiations on enterprise bargaining agreements in Western Australia and New South Wales, Australia, the investment firm stated.CSL  ResMed  has shown margin expansion due to management improving operating margins, with ResMed's initial concern of higher freight costs on margins \"more than offset\" as expectations it will normalize into fiscal 2025, according to the note.ResMed, Cochlear , Regis Healthcare, and Sonic Healthcare appear to Jarden Research to be best positioned for more mergers and acquisitions and capital management, while Healius and Ramsay Healthcare are looking at selling assets ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK7501","REG.AU","BK7511","BK7007","CSL.AU","HLS.AU","BK7113","TLX.AU","XKO.AU","HCSG","CAJ.AU","RMD.AU","XAO.AU","RHC.AU","BK7124","IDX.AU","BK7508","BK7509","COH.AU","BK7067","SHL.AU","BK4137"],"gpt_icon":0},{"id":"2468611833","title":"Cochlear (ASX:COH) Appoints New CFO Amid Strong Financials and Strategic Buyback Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2468611833","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468611833?lang=en_us&edition=fundamental","pubTime":"2024-09-20 16:37","pubTimestamp":1726821426,"startTime":"0","endTime":"0","summary":"Cochlear  is navigating a complex environment marked by both strengths and challenges. Recent highlights include a 15% revenue increase and significant R&D investments, contrasted with slowing emerging market growth and high valuation concerns. In the discussion that follows, we will explore Cochlear's financial health, operational inefficiencies, strategic growth initiatives, and external threats to provide a comprehensive overview of the company's current business situation.Click here to discover the nuances of Cochlear with our detailed analytical report.Cochlear has several promising opportunities to enhance its market position. The company is actively working on closing the gap in market uptake with its Osia product, which CEO Dig Howitt believes is well-suited for market needs. Increasing awareness and referrals for hearing loss treatments are also key strategies. The company is making significant strides in new product development, meeting various milestones across its developme","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oY9vQNBdaHAXW3k6VZJztA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cochlear-asx-coh-appoints-cfo-083706848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["COH.AU","BK7007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cochlear.com","stockEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0309},{"period":"3month","weight":-0.0277},{"period":"6month","weight":-0.1008},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.0008}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":-0.0212},{"period":"3month","weight":-0.0228},{"period":"6month","weight":-0.0014},{"period":"1year","weight":0.135},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaboration with GN Hearing to develop integrated hearing solutions. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.758621,"avgChangeRate":0.023492},{"month":2,"riseRate":0.62069,"avgChangeRate":0.017459},{"month":3,"riseRate":0.586207,"avgChangeRate":0.013109},{"month":4,"riseRate":0.448276,"avgChangeRate":0.008512},{"month":5,"riseRate":0.655172,"avgChangeRate":0.0191},{"month":6,"riseRate":0.62069,"avgChangeRate":0.019101},{"month":7,"riseRate":0.62069,"avgChangeRate":0.033589},{"month":8,"riseRate":0.482759,"avgChangeRate":-0.003204},{"month":9,"riseRate":0.586207,"avgChangeRate":0.013697},{"month":10,"riseRate":0.586207,"avgChangeRate":0.02767},{"month":11,"riseRate":0.714286,"avgChangeRate":0.027547},{"month":12,"riseRate":0.551724,"avgChangeRate":0.000352}],"exchange":"ASX","name":"COCHLEAR LTD","nameEN":"COCHLEAR LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COCHLEAR LTD(COH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest COCHLEAR LTD(COH.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"COCHLEAR LTD,COH.AU,COCHLEAR LTD股票,COCHLEAR LTD股票老虎,COCHLEAR LTD股票老虎国际,COCHLEAR LTD行情,COCHLEAR LTD股票行情,COCHLEAR LTD股价,COCHLEAR LTD股市,COCHLEAR LTD股票价格,COCHLEAR LTD股票交易,COCHLEAR LTD股票购买,COCHLEAR LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COCHLEAR LTD(COH.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest COCHLEAR LTD(COH.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}